If I redid my calculations, allowing for the probabilities of success in the various phases, tweaking them moderately for topical application, and what the company can expect to be flogged for with a successful Phase 2, I reckon maybe 60 cents, so I think Death Star is a bit low and any self-respecting venture capitalist having done his sums would buy up to the 15-20 cents range and give the (present) board and Wasps a fright.
Ann: Botanix Presents at Fall Clinical Dermatology Conference, page-157
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.005(1.37%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 36.0¢ | $391.8K | 1.080M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 160000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 11013 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
